Cargando…
P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429528/ http://dx.doi.org/10.1097/01.HS9.0000969424.38447.63 |
| _version_ | 1785090737415651328 |
|---|---|
| author | Simon, Florian Ligtvoet, Rudy Noesslinger, Thomas Bohn, Jan-Paul Von Tresckow, Julia Liersch, Rüdiger Gaska, Tobias Jentsch-Ullrich, Kathleen Koenigsmann, Michael Wolff, Thomas Schwaner, Ingo Wolf, Dominik Schneider, Christof Tausch, Eugen Stilgenbauer, Stephan Kreuzer, Karl-Anton Robrecht, Sandra Fink, Anna-Maria Fürstenau, Moritz Fischer, Kirsten Goede, Valentin Hallek, Michael Eichhorst, Barbara |
| author_facet | Simon, Florian Ligtvoet, Rudy Noesslinger, Thomas Bohn, Jan-Paul Von Tresckow, Julia Liersch, Rüdiger Gaska, Tobias Jentsch-Ullrich, Kathleen Koenigsmann, Michael Wolff, Thomas Schwaner, Ingo Wolf, Dominik Schneider, Christof Tausch, Eugen Stilgenbauer, Stephan Kreuzer, Karl-Anton Robrecht, Sandra Fink, Anna-Maria Fürstenau, Moritz Fischer, Kirsten Goede, Valentin Hallek, Michael Eichhorst, Barbara |
| author_sort | Simon, Florian |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429528 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104295282023-08-17 P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL Simon, Florian Ligtvoet, Rudy Noesslinger, Thomas Bohn, Jan-Paul Von Tresckow, Julia Liersch, Rüdiger Gaska, Tobias Jentsch-Ullrich, Kathleen Koenigsmann, Michael Wolff, Thomas Schwaner, Ingo Wolf, Dominik Schneider, Christof Tausch, Eugen Stilgenbauer, Stephan Kreuzer, Karl-Anton Robrecht, Sandra Fink, Anna-Maria Fürstenau, Moritz Fischer, Kirsten Goede, Valentin Hallek, Michael Eichhorst, Barbara Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429528/ http://dx.doi.org/10.1097/01.HS9.0000969424.38447.63 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Simon, Florian Ligtvoet, Rudy Noesslinger, Thomas Bohn, Jan-Paul Von Tresckow, Julia Liersch, Rüdiger Gaska, Tobias Jentsch-Ullrich, Kathleen Koenigsmann, Michael Wolff, Thomas Schwaner, Ingo Wolf, Dominik Schneider, Christof Tausch, Eugen Stilgenbauer, Stephan Kreuzer, Karl-Anton Robrecht, Sandra Fink, Anna-Maria Fürstenau, Moritz Fischer, Kirsten Goede, Valentin Hallek, Michael Eichhorst, Barbara P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL |
| title | P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL |
| title_full | P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL |
| title_fullStr | P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL |
| title_full_unstemmed | P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL |
| title_short | P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL |
| title_sort | p630: safety and treatment adherence with acalabrutinib in very old (≥80y) and/or frail patients with chronic lymphocytic leukemia (cll) - interim safety analysis of the ongoing phase-ii cll-frail trial |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429528/ http://dx.doi.org/10.1097/01.HS9.0000969424.38447.63 |
| work_keys_str_mv | AT simonflorian p630safetyandtreatmentadherencewithacalabrutinibinveryold80yandorfrailpatientswithchroniclymphocyticleukemiacllinterimsafetyanalysisoftheongoingphaseiicllfrailtrial AT ligtvoetrudy p630safetyandtreatmentadherencewithacalabrutinibinveryold80yandorfrailpatientswithchroniclymphocyticleukemiacllinterimsafetyanalysisoftheongoingphaseiicllfrailtrial AT noesslingerthomas p630safetyandtreatmentadherencewithacalabrutinibinveryold80yandorfrailpatientswithchroniclymphocyticleukemiacllinterimsafetyanalysisoftheongoingphaseiicllfrailtrial AT bohnjanpaul p630safetyandtreatmentadherencewithacalabrutinibinveryold80yandorfrailpatientswithchroniclymphocyticleukemiacllinterimsafetyanalysisoftheongoingphaseiicllfrailtrial AT vontresckowjulia p630safetyandtreatmentadherencewithacalabrutinibinveryold80yandorfrailpatientswithchroniclymphocyticleukemiacllinterimsafetyanalysisoftheongoingphaseiicllfrailtrial AT lierschrudiger p630safetyandtreatmentadherencewithacalabrutinibinveryold80yandorfrailpatientswithchroniclymphocyticleukemiacllinterimsafetyanalysisoftheongoingphaseiicllfrailtrial AT gaskatobias p630safetyandtreatmentadherencewithacalabrutinibinveryold80yandorfrailpatientswithchroniclymphocyticleukemiacllinterimsafetyanalysisoftheongoingphaseiicllfrailtrial AT jentschullrichkathleen p630safetyandtreatmentadherencewithacalabrutinibinveryold80yandorfrailpatientswithchroniclymphocyticleukemiacllinterimsafetyanalysisoftheongoingphaseiicllfrailtrial AT koenigsmannmichael p630safetyandtreatmentadherencewithacalabrutinibinveryold80yandorfrailpatientswithchroniclymphocyticleukemiacllinterimsafetyanalysisoftheongoingphaseiicllfrailtrial AT wolffthomas p630safetyandtreatmentadherencewithacalabrutinibinveryold80yandorfrailpatientswithchroniclymphocyticleukemiacllinterimsafetyanalysisoftheongoingphaseiicllfrailtrial AT schwaneringo p630safetyandtreatmentadherencewithacalabrutinibinveryold80yandorfrailpatientswithchroniclymphocyticleukemiacllinterimsafetyanalysisoftheongoingphaseiicllfrailtrial AT wolfdominik p630safetyandtreatmentadherencewithacalabrutinibinveryold80yandorfrailpatientswithchroniclymphocyticleukemiacllinterimsafetyanalysisoftheongoingphaseiicllfrailtrial AT schneiderchristof p630safetyandtreatmentadherencewithacalabrutinibinveryold80yandorfrailpatientswithchroniclymphocyticleukemiacllinterimsafetyanalysisoftheongoingphaseiicllfrailtrial AT tauscheugen p630safetyandtreatmentadherencewithacalabrutinibinveryold80yandorfrailpatientswithchroniclymphocyticleukemiacllinterimsafetyanalysisoftheongoingphaseiicllfrailtrial AT stilgenbauerstephan p630safetyandtreatmentadherencewithacalabrutinibinveryold80yandorfrailpatientswithchroniclymphocyticleukemiacllinterimsafetyanalysisoftheongoingphaseiicllfrailtrial AT kreuzerkarlanton p630safetyandtreatmentadherencewithacalabrutinibinveryold80yandorfrailpatientswithchroniclymphocyticleukemiacllinterimsafetyanalysisoftheongoingphaseiicllfrailtrial AT robrechtsandra p630safetyandtreatmentadherencewithacalabrutinibinveryold80yandorfrailpatientswithchroniclymphocyticleukemiacllinterimsafetyanalysisoftheongoingphaseiicllfrailtrial AT finkannamaria p630safetyandtreatmentadherencewithacalabrutinibinveryold80yandorfrailpatientswithchroniclymphocyticleukemiacllinterimsafetyanalysisoftheongoingphaseiicllfrailtrial AT furstenaumoritz p630safetyandtreatmentadherencewithacalabrutinibinveryold80yandorfrailpatientswithchroniclymphocyticleukemiacllinterimsafetyanalysisoftheongoingphaseiicllfrailtrial AT fischerkirsten p630safetyandtreatmentadherencewithacalabrutinibinveryold80yandorfrailpatientswithchroniclymphocyticleukemiacllinterimsafetyanalysisoftheongoingphaseiicllfrailtrial AT goedevalentin p630safetyandtreatmentadherencewithacalabrutinibinveryold80yandorfrailpatientswithchroniclymphocyticleukemiacllinterimsafetyanalysisoftheongoingphaseiicllfrailtrial AT hallekmichael p630safetyandtreatmentadherencewithacalabrutinibinveryold80yandorfrailpatientswithchroniclymphocyticleukemiacllinterimsafetyanalysisoftheongoingphaseiicllfrailtrial AT eichhorstbarbara p630safetyandtreatmentadherencewithacalabrutinibinveryold80yandorfrailpatientswithchroniclymphocyticleukemiacllinterimsafetyanalysisoftheongoingphaseiicllfrailtrial |